THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER VACCINATION AGAINST COVID-19 – A CASE REPORT

  • PANCHAL Y
  • M PATEL M
  • V PATEL M
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare but fatal thrombotic microangiopathy. Circulating AntiADAMTS13 antibodies produced in response to various triggering events, such as vaccinations, autoimmune disorders, malignancy, and administration of several drugs lead to acquired TTP (aTTP). This case concerns a 26-year-old male with aTTP after receiving the second dose of the Covishield vaccine (Oxford-AstraZeneca COVID-19 vaccine, code-named AZD1222). He presented with bruises, petechia, fatigue, dyspnea, and arthralgia post-vaccination. Laboratory reports showed thrombocytopenia, hemolytic anemia, a significant ADAMTS13 deficiency, and a high level of autoantibody titer against ADAMTS13. We treated the patient with plasma exchange therapy and prednisolone, and after the treatment, he recovered.

Cite

CITATION STYLE

APA

PANCHAL, Y. N., M PATEL, M., & V PATEL, M. (2022). THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER VACCINATION AGAINST COVID-19 – A CASE REPORT. Asian Journal of Pharmaceutical and Clinical Research, 1–3. https://doi.org/10.22159/ajpcr.2022.v15i4.44241

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free